News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,329 Results
Type
Article (13872)
Company Profile (295)
Press Release (246162)
Section
Business (79323)
Career Advice (150)
Deals (13180)
Drug Delivery (32)
Drug Development (50285)
Employer Resources (31)
FDA (5670)
Job Trends (5113)
News (144061)
Policy (10014)
Tag
Academia (901)
Alliances (21469)
Alzheimer's disease (736)
Approvals (5645)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4498)
Biotechnology (242)
Breast cancer (66)
Cancer (699)
Cardiovascular disease (62)
Career advice (131)
CAR-T (57)
Cell therapy (178)
Clinical research (39815)
Collaboration (239)
Compensation (99)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (798)
Diabetes (73)
Diagnostics (1201)
Earnings (28977)
Events (46852)
Executive appointments (193)
FDA (5964)
Funding (252)
Gene editing (55)
Gene therapy (148)
GLP-1 (301)
Government (1063)
Healthcare (6532)
Infectious disease (1037)
Inflammatory bowel disease (94)
IPO (7182)
Job creations (859)
Job search strategy (126)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6102)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (844)
Northern California (951)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24984)
Pharmaceutical (50)
Phase I (14009)
Phase II (18522)
Phase III (11736)
Pipeline (324)
Postmarket research (846)
Preclinical (5929)
Radiopharmaceuticals (205)
Rare diseases (169)
Real estate (1409)
Regulatory (8206)
Research institute (930)
Southern California (868)
Startups (1964)
United States (7654)
Vaccines (160)
Weight loss (76)
Date
Today (27)
Last 7 days (419)
Last 30 days (2247)
Last 365 days (20739)
2024 (19058)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16832)
Australia (2839)
California (2158)
Canada (718)
China (166)
Colorado (82)
Connecticut (86)
Europe (36249)
Florida (232)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1712)
Michigan (48)
Minnesota (94)
New Jersey (549)
New York (615)
North Carolina (399)
Northern California (951)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (868)
Texas (232)
Washington State (221)
260,329 Results for "tavros therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.
May 14, 2024
·
3 min read
Business
Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Tavros Therapeutics, Inc. and OpenBench, Inc. today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term.
April 27, 2023
·
3 min read
Bio NC
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Tavros Therapeutics today announced the completion of a $7.5 million oversubscribed Seed II financing.
September 27, 2022
·
2 min read
Business
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs
Tavros Therapeutics, Inc. and Vividion Therapeutics, Inc. today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.
October 12, 2022
·
5 min read
Business
Bayer’s Vividion Bets up to $930M for Tavros Oncology Partnership
Vividion Therapeutics and Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
October 12, 2022
·
2 min read
·
Tristan Manalac
Business
OpenBench and Tavros Therapeutics Announce Collaboration to Pursue First-in-class Cancer Target
Tavros Therapeutics, and OpenBench, today announced a collaboration in which OpenBench will identify novel, potent antagonists against an undisclosed cancer target that was identified by Tavros’s proprietary functional genomics platform.
December 2, 2021
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
Layoffs
Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization
Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.
November 7, 2024
·
2 min read
·
Angela Gabriel
1 of 26,033
Next
